Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response

Han Zhang², Yijun Wu², Hao Li³, Liping Sun² and Xiangkai Meng¹*

Abstract

Background: The prognosis of high grade serous ovarian cancer (HGSOC) patients is closely related to the immune microenvironment and immune response. Based on this, the purpose of this study was to construct a model to predict chemosensitivity and prognosis, and provide novel biomarkers for immunotherapy and prognosis evaluation of HGSOC.

Methods: GSE40595 (38 samples), GSE18520 (63 samples), GSE26712 (195 samples), TCGA (321 samples) and GTEx (88 samples) were integrated to screen differential expressed genes (DEGs) of HGSOC. The prognosis related DEGs (DEPGs) were screened through overall survival analysis. The DEGs-encoded protein–protein interaction network was constructed and hub genes of DEPGs (DEPHGs) were generated by STRING. Immune characteristics of the samples were judged by ssGSEA, ESTIMATE and CYBERSORT. TIMER was used to analyze the relationship between DEPHGs and tumor-infiltrating immunocytes, as well as the immune checkpoint genes, finally immune-related DEPHGs (IDEPHGs) were determined, and whose expression in 12 pairs of HGSOC tissues and tumor-adjacent tissues were analyzed by histological verification. Furthermore, the chemosensitivity genes in IDEPHGs were screened according to GSE15622 (n = 65). Finally, two prediction models of paclitaxel sensitivity score (PTX score) and carboplatin sensitivity score (CBP score) were constructed by lasso algorithm. The area under curve was calculated to estimate the accuracy of candidate gene models in evaluating chemotherapy sensitivity.

Results: 491 DEGs were screened and 37 DEGs were identified as DEPGs, and 11 DEPHGs were further identified. Among them, CXCL13, IDO1, PI3, SPP1 and TRIM22 were screened as IDEPHGs and verified in the human tissues. Further analysis showed that IDO1, PI3 and TRIM22 could independently affect the chemotherapy sensitivity of HGSOC patients. The PTX score was significantly better than TRIM22, PI3, SPP1, IDO1 and CXCL13 in predicting paclitaxel sensitivity, so was CBP score in predicting carboplatin sensitivity. What's more, both of the HGSOC patients with high PTX score or high CBP score had longer survival time.

Conclusions: Five IDEPHGs identified through comprehensive bioinformatics analysis were closely related with the prognosis, immune microenvironment and chemotherapy sensitivity of HGSOC. Two prediction models based on IDEPHGs might have potential application of chemotherapy sensitivity and prognosis for patients with HGSOC.
Keywords: Ovarian cancer, Differentially expressed genes, Prognosis, Immune, Chemosensitivity

Introduction
Ovarian cancer (OC) is a common gynecological malignancy. The 5-year survival rate of OC patients remains low because of the high heterogeneity of the tumor and high incidence of drug resistance during chemotherapy [1–5]. The standard treatment for OC is maximal cytoreductive surgery and postoperative paclitaxel-platinum combined chemotherapy, with a higher survival rate than other regimens, including cyclophosphamide-platinum/gemcitabine and so on [6]. Most patients develop treatment resistance after prolonged treatment, and almost all patients with recurrent ovarian cancer (ROC) eventually develop platinum resistance [7, 8]. But paclitaxel still keeps anti-tumorigenic activity for patients with platinum-resistant OC or platinum-resistant ROC [9]. In recent years, new immunotherapy strategies like immune checkpoint inhibitors therapy, cancer vaccine inoculation and adoptive immunotherapy have had a broad prospect for OC patients with platinum resistance in clinical treatment. In addition, new immunotherapies such as chimeric antigen receptor T cells (CAR-T) and mesothelin (meso) have progressed into clinical trials for the treatment of OC [10].

High grade serous ovarian cancer (HGSOC) is highly malignant and can easily metastasize to the abdominal cavity causing severe ascites and intestinal obstruction as the main type of epithelial OC, which occupies 70%-80% of epithelial ovarian cancer deaths [11]. The clinical manifestations of HGSOC are atypical and lack of specific detection methods, and the five-year survival rate is only 15–25%, so it is urgent to develop precise treatment for HGSOC [12, 13].

Traditionally, clinical stage, the status of cytoreductive surgery and sensitivity to chemotherapeutic drugs are fundamental factors that predict the prognosis of patients with OC [14]. However, because ovarian cancer is a heterogeneous disease characterized by complex molecular and genetic changes, the survival rate and treatment response of cases with similar clinical features are very different, and it is more reasonable to judge the prognosis at the molecular biology level [15]. In recent years, a series of studies has confirmed that the expression level of genes in patients can significantly determine their long-term survival or recurrence after chemotherapy, suggesting that crucial genes can be selected as biomarkers to provide a reference for prognosis prediction and treatment choice of patients [16, 17].

The immune system plays an important regulatory role in the genesis and progression of OC, and the tumor immune reaction is closely correlated with the clinical efficacy and the outcome of OC cases. Eiichi Sato et al. reported that tumor-infiltrating lymphocytes (TILs) in the immune microenvironment of ovarian cancer could assist in tumor cell removal [18]. Additionally, the increase in the ratio of CD8+/CD4+ T lymphocytes could improve the overall survival rate of patients with OC [19]. Some DEGs in patients could participate in the regulation of immunocyte infiltration in ovarian cancer, leading to immune escape and adverse clinical outcome by promoting the production of cytokines and inhibiting the proliferation of effector T lymphocytes [20].

Activating immune reaction and destroying the proliferation and invasion of OC have become a hot spot in clinical immunotherapy because of the close relationship between OC malignant progression and immune escape mechanism. Immune destruction against tumor is a multi-step and coordinated process, which can take targeted regulation at several key points (immune checkpoints) to induce the tumor rejection. Immune checkpoint inhibitors (ICPIs) can prevent immune escape and induce the immune system to produce an anti-tumor response by blocking the activation of T lymphocytes surface checkpoint proteins, thus improving the efficacy of chemotherapy and effectively prolonging the survival time of tumor cases [21]. Now that the role of ICPIs in ovarian cancer is more moderate and changeable, the immunotherapy of ovarian cancer must comprehensively consider the immune suppressive network in the tumor microenvironment, as well as the inherent biological characteristics of the tumor that also plays a decisive role [22]. Accordingly, searching the differential expressed genes of ovarian cancer with a significant correlation with tumor-infiltrating immunocytes and immune checkpoints, and exploring biomarkers that could predict the responsiveness of patients to different types of immunotherapy are of considerable significance, which contributes to choose the best combination therapy and reduce the side effects [23].

Therefore, this study intends to analyze the association between prognosis-related genes and tumor-infiltrating immunocytes, as well as immune checkpoint genes, in ovarian cancer through bioinformatics methods. Thus, the potential prognostic biomarkers that are closely associated with the tumor immune response and curative effect can be explored, and scoring models can be constructed, providing potential markers for prognosis and chemotherapy sensitivity evaluation, as well as new valid targets to treat OC.
Materials and methods
Microarray data
The Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/) includes high-throughput sequencing data, gene chips, microarrays and other massive data information that users can download for free. We obtained three gene expression profiles (GSE40595, GSE18520 and GSE26712) from the GEO database. Three microarray datasets were integrated after removing batch effect using R-package “sva” (http://www.bioconductor.org) [24]. Among them, GSE40595 included 32 HGSOC and 6 normal samples, GSE18520 contained 53 HGSOC and 10 normal samples, and GSE26712 included 185 HGSOC and 10 normal samples [25–27].

Besides, we got GSE15622 dataset obtaining the information about chemotherapy sensitivity of OC from GEO database, and it included 36 OC samples taking paclitaxel monotherapy and 29 OC samples taking carboplatin monotherapy [28].

TCGA is a highly reliable high-throughput database containing DNA, RNA and protein information from various human cancers [29]. Sequencing data and clinical information of TCGA-OV 379 OC samples were obtained from UCSC database (http://xenabrowser.net/hub/), and finally 321 HGSOC samples were incorporated after screening according to the clinical information [30]. At the same time, we supplemented the sequencing data of 88 normal ovarian epithelial tissues through GTEx database, and took joint analysis with HGSOC samples from TCGA database [31].

Data processing
We used “limma” package (http://www.bioconductor.org) to perform background correction and differential gene analysis respectively on chip data and transcriptome high-throughput sequencing data [32]. We set adj. P < 0.05 and |logFC| > 1 as the cut-off criteria. Thus, we distinguished DEGs between HGSOC and normal samples in GSE40595, GSE18520 and GSE26712, as well as those in TCGA-OV and GTEx datasets. And we took the intersection of the above DEGs for subsequent analysis.

Volcano maps and heat maps were drawn to visualize the results of DEGs analysis using “ggplot2” package (https://ggplot2.tidyverse.org) and “pheatmap” package (https://CRAN.R-project.org/package=pheatmap) [33]. The volcano map took the multiple of gene expression difference as the absissa, and the logarithm of adj. P value as the ordinate, and can directly reflect the DEGs in two groups of samples through scatter diagram. The heat map reflected the data information in gene expression matrix by the change of color, and took clustering analysis of abundance similarity among samples.

Survival analysis
We finally obtained 320 HGSOC cases with complete survival information out of 321 HGSOC cases from TCGA-OV database after screening the clinical information. “Survival” package (https://CRAN.R-project.org/package=survival) was used for Kaplan–Meier survival analysis, and we set median single gene expression as the cut-off criteria to divide patients into high gene expression group and low gene expression group.

Then we estimated the effect of single gene on overall survival (OS) rate in HGSOC patients and evaluated the survival curve by log-rank test. We set log rank P < 0.05 as the cut-off criteria. In addition, univariate COX regression analysis was used to calculate univariate hazard ratio (HR) through “survival” package, and multivariate COX regression analysis was used to identify independent prognostic factors.

Clinical specimens collection and histological verification
Twelve pairs of tumor tissues and tumor-adjacent tissues were collected in accordance with the Declaration of Helsinki and legal regulations from HGSOC patients in the First Hospital of China Medical University. Tumor-adjacent tissue was defined as normal ovarian tissue > 5 cm away from the tumor. The study was approved by the Ethics Committee of the First Hospital of China Medical University. The written informed consent has been obtained from each participant before specimen collection.

After crushing and grinding at low temperature, tissue RNA extraction was performed according to the Trizol Reagent (Takara, Japan) protocol. RNA was reversely transcribed into cDNA according to the MonScript™ rTIII All-in-One Mix with dsDNase (Monad, China) protocol. 2 μg total RNA of each sample was added to 40 μL reverse transcription reaction system. The temperature protocol of reverse transcription was as follows: 37 °C for 2 min to remove the contamination of genomic DNA, then 55 °C for 15 min and 85 °C for 5 min. The products were stored at −20 °C. Relative mRNA expression levels were detected by real-time quantitative PCR (RT-qPCR) using SYBR® Premix Ex Taq™ II (Takara, Japan).

A standard three-step real-time PCR program was used with an annealing temperature of 58°C and 40 cycles of amplification. β-actin was selected as the internal reference. All of the RT-qPCR curves were with single peak. The relative quantification in RT-qPCR was calculated by 2^(-ΔΔCt) method. P < 0.05 was considered to imply significant results. The sequences of primers were listed in the Additional file 5: Table S5.
Prognostic PPI network construction and core module identification

The Search Tool for the Retrieval of Interacting Genes (STRING, https://string-db.org/) is an online tool to analyze protein interactions in multiple ways [34]. First, we used the tool to establish the protein–protein interaction (PPI) network of DEGs intersection and search for interacting genes. Then, we visualized the PPI network using MCODE plug-in from Cytoscape software and identified core modules [35]. MCODE’s (molecular complex detection) main function is clustering in protein network and building functional modules, which can find out the closely-associated areas that may represent highly function-related molecular complexes according to the connection of each node in PPI network.

ssGSEA, ESTIMATE and CYBERSORT

We collected 29 immune related gene sets from published literatures, and among them there were 569 immune related genes involved (Additional file 1: Table S1) [36–38]. “GSVA” package (http://www.biomedicalcentral.com/1471-2105/14/7) uses single sample gene set enrichment analysis (ssGSEA) to calculate rank value of every gene from expression profiles and quantify the enrichment fraction of each immune related gene in a single sample, which can help judge the activity of immune cells, immune function or immune pathway of each sample [39].

The "ESTIMATE" package (https://R-Forge.R-project.org/projects/estimate/) is also based on the ssGSEA principle to assess the stroma content, the proportion of immune cells and the purity of the tumor in every single sample, which is mutually verified with the results of the “GSVA” package [40].

CYBERSORT is an analytical tool developed by Newman et al., which can deconvolute the expression matrices based on the known reference sets to estimate the abundance of different types of immune cells in the mixed cell population [41]. The expression matrix is analyzed by CYBERSORT through "e1071" package (http://cran.r-project.org/web/packages/e1071/index.html), and the results are visualized through "pheatmap", "vioplot" and "corrplot" packages.

Correlation analysis among hub gene expression and immunocyte infiltration, as well as immune checkpoints

TIMER (https://cistrome.shinyapps.io/timer/), which can be applied to analyze tumor immune relevance, was used to analyze the correlation between gene expression from high-throughput sequencing dataset of serous ovarian cancer in TCGA-OV and six tumor infiltrating immunocytes (B lymphocytes, CD8+ T lymphocytes, CD4+ T lymphocytes, neutrophils, macrophages and dendritic cells), as well as five immune checkpoint genes (PDCD1, CD274, CTLA4, HAVCR2 and TOX) [42]. Significance levels were set at the 5% level.

Furthermore, CYBERSORT was used to verify the results of TIMER.

Gene set enrichment analysis (GSEA)

The sequencing data of 321 HGSOC samples from TCGA-OV database were divided into two groups according to the median of single gene expression level. The enrichment scores (ES) of pathway-related gene sets in each group were calculated by GSEA software (4.1.0), and reflected the degree to which a given gene set is represented in a ranked list of genes [43]. We choose adj.P < 0.05 and top 20 signaling pathway rank as threshold.

Identification of genes related to chemosensitivity of paclitaxel / carboplatin in HGSOC patients

We divided patients from GSE15622 into paclitaxel resistant group, paclitaxel sensitive group, carboplatin resistant group and carboplatin sensitive group according to their clinical information, and respectively extracted the expression levels of single gene (CXCL13, IDO1, PI3, SPP1 and TRIM22) in the expression profile and then screened the DEGs between groups. Finally, we visualized the data using “ggplot2” package (https://ggplot2.tidyverse.org).

Gene ontology (GO) analysis

GO analysis is widely used in the field of bioinformatics, covering three aspects of biology: cellular components (CC), molecular function (MF), and biological processes (BP). Through GO analysis, it is possible to understand the biological functions of DEGs enrichment. The "limma" package was used to screen the DEGs between groups, the "clusterProfiler" package was used for GO enrichment analysis [44], and the "enrichplot" and "ggplot2" packages were used to visualize the results.

Construction of PTX score model and CBP score model

We chose GSE15622 dataset to screen genes incorporated in models from CXCL13, IDO1, PI3, SPP1 and TRIM22 using lasso algorithm by "glmnet" package, and calculated the corresponding coefficients [45]. The "glmnet" package uses the cyclic coordinate descent method to achieve the final lasso regression model, and each parameter included is optimized and cycled while keeping the other parameters fixed until the coefficient is stable. Lasso algorithm can filter out variables and optimize the complexity of the model. Variable filtering refers to
including variables selectively into the model to get better performance parameters. Complexity adjustment is to adjust the model complexity through changing a series of parameters to avoid overfitting. Finally, the lasso algorithm can simplify the model and get the optimal calculation formula.

Thus, we could get PTX score model and CBP score model from expression profile data and corresponding single gene coefficients, and the formula was as follows:

$$\text{Score} = \sum_{i=1}^{n} \text{Coef}(i) \cdot X(i)$$

$N$ is the number of included genes, $\text{Coef}(i)$ is the coefficient, $X(i)$ is the gene expression level.

**Evaluation of the chemotherapy sensitivity of PTX score and CBP score**

Firstly, we compared the differences of PTX score between paclitaxel resistant group and paclitaxel sensitive group, and differences of CBP score between carboplatin resistant group and carboplatin sensitive group according to the clinical information. Secondly, we divided patients into groups based on the median value of PTX score or CBP score, and calculated the percentages of drug-resistant and drug-sensitive groups alone. Finally, we used GraphPad Prism 8 software to draw and visualize ROC curve, calculated the area under curve (AUC) and estimated the accuracy of candidate gene models in evaluating chemotherapy sensitivity.

**Evaluation of the prognostic value of PTX score and CBP score**

We calculated the PTX score and CBP score of 320 HGSOC samples with complete survival information from TCGA-OV database using the formula in "Evaluation of the chemotherapy sensitivity of PTX score and CBP score" section, and we used "survival" package for Kaplan–Meier survival analysis. The patients were divided into two groups according to the median score. Then we evaluated the influence of score on HGSOC patients’ overall survival (OS) rate, and the criterion was same as "Survival analysis" section.

**Statistical methods**

The data were analyzed statistically by R Studio (Version 3.7.0), Perl (Version 5.28.1) and GraphPad Prism (Version 8.0.2.263). Student t test and Wilcoxon signed rank test were used to analyze the differences between the two groups. And the correlation was analyzed by Spearman-rank correlation. $P < 0.05$ was considered to be statistically significant.
Analysis about tumor-infiltrating immunocytes and immune functional features

We used ssGSEA to analyze and visualize the immune infiltrating cells and immune functional features from normal ovarian epithelium and HGSOC samples in TCGA + GTEx cohort(left) and GEO cohort(right) (Fig. 3a). The differences of immune cells scores, stroma scores, immune infiltrating cells, immune functions and activities of pathways between normal samples and HGSOC samples could be directly observed, and it was more obvious in TCGA + GTEx cohort.

We found that the infiltration of dendritic cells (DCs), activated dendritic cells (aDCs), immature dendritic cells (iDCs), plasmacytoid dendritic cells (pDCs), CD8+ T cells and Th1 cells generally increased while the infiltration of B cells decreased when further compared the immune infiltrating cells, immune functions and activities of pathways between normal samples and HGSOC samples in two cohorts (Fig. 3b). Similarly, the immune functions or activities of pathways including the APC co-suppression, APC co-stimulation, immune checkpoints, parainflammation and I-type IFN reaction enhanced in HGSOC samples (Fig. 3c).

Fig. S2a showed the proportion of 22 kinds of immune cells in each sample. Finally, we integrated the results of ssGSEA and CYBERSORT analysis, and found that the dendritic cells infiltration was consistently increased in HGSOC samples (Fig.S2b).

Correlation analysis among prognosis-related hub genes and tumor-infiltrating immunocytes, as well as immune checkpoints

Previous studies confirmed that immune system played an important part in the genesis, progression, prognosis and treatment of ovarian cancer. We found that the immunocyte infiltration, immune functions and related activities of pathways of HGSOC patients greatly changed from "Analysis about tumor-infiltrating immunocytes
Fig. 2 Identification of prognosis-related DEGs. a Prognosis-related DEGs PPI network constructed by STRING. Different colors represent the preliminary clustering by STRING according to protein functions. b Core module after further clustering the PPI network by MCODE. The area of the circle represents the closeness of the connection between each node and other nodes, and the more connections, the larger the area of the circle. c–m Survival curves of hub genes by KM analysis (n = 320). The horizontal axis is time, and the longitudinal axis is the overall survival rate of corresponding time. The red color represents the group of genes with high expression, and the blue color represents the group of genes with low expression. c CXCL13; d CXCR4; e FGF13; f IDO1; g KIT; h LYVE1; i PI3; j SLC2A1; k SNCA; l SPP1; m TRIM22
Fig. 3  Tumor-infiltrating immunocytes and immune functional features of the cohorts.  

**a** Immune characteristic heat maps of TCGA+GTEx cohort (left) and GEO cohort (right). TCGA: n = 321, GTEx: n = 88, GEO: n = 296 (cancer: 270, normal: 26). Tumor purity, ESTIMATE total score, immune cell score, stroma score, immune infiltrating cells, immune function and pathway activity of every single sample are annotated by color depth.  

**b** Comparison of immune infiltrating cells between normal ovarian epithelium samples (green) and HGSOC samples (yellow) in TCGA+GTEx cohort (left) and GEO cohort (right). The Boxes horizontal line represents the median value, and the top line and bottom line represent the 25th and 75th percentiles (interquartile range). The whiskers encompass 1.5 times the interquartile range. The differences were analyzed by Wilcoxon signed rank test (*, P < 0.05; **, P < 0.01; ***, P < 0.0001).  

**c** Comparisons of immune functions and pathway activities between normal ovarian epithelium samples (green) and HGSOC samples (yellow) in TCGA+GTEx cohort (left) and GEO cohort (right), and the annotation is same as **b**.
and immune functional features” part. Thus, we took further correlation analysis among HGSOC prognosis-related genes from "Identification of prognosis-related DEGs and construction of PPI network and core module” part and tumor-infiltrating immunocytes, as well as immune checkpoints.

According to the expression profile of serous OC samples from TCGA database, we analyzed the relevance between the expressions of 11 genes including CXCL13 and the contents of immune infiltrating cells like B cells, CD8+ T cells and so on from samples (Additional file 3: Table S3). Further, the analysis of the expression collinearity between 11 genes and 5 immune checkpoint genes including PDCD1, CD274, CTLA4, HAVCR2 and TOX was made (Additional file 4: Table S4). We screened CXCL13, IDO1, PI3, SPP1 and TRIM22 in all with the strongest correlation with HGSOC immune infiltrating cells and immune checkpoints according to related coefficients and P values (Tables 1, 2), and visualized the results by scatter diagram (Fig. 4a, b).

In addition to TIMER analysis, CYBERSORT was used to analyze the relationship between five genes and immune infiltrating cells in TCGA-HGSOC. The results showed that CXCL13 had a certain linear relationship with CD8+ T cells and CD4+ T cells. IDO1 and B cells, CD8+ T cells, CD4+ T cells; PI3 and neutrophils; SPP1

| Table 1 | The results of relevance analysis between DEPHGs of HGSOC and immunocytes (top five) |
|---------|----------------------------------|
| Variable | B Cell | CD8+ T Cell | CD4+ T Cell | Macrophage | Neutrophil | Dendritic Cell |
| CXCL13  | Partial cor | 0.110 | 0.339 | 0.308 | 0.058 | 0.371 | 0.358 |
| P.value  | 0.016 | 0.000 | 0.201 | 0.000 | 0.000 | 0.000 |
| IDO1    | Partial cor | 0.251 | 0.472 | 0.185 | -0.013 | 0.502 | 0.425 |
| P-value  | 0.000 | 0.004 | 0.835 | 0.000 | 0.000 | 0.000 |
| PI3     | Partial cor | -0.029 | -0.029 | 0.071 | -0.033 | 0.224 | 0.083 |
| P-value  | 0.520 | 0.529 | 0.472 | 0.000 | 0.069 |
| SPP1    | Partial cor | 0.048 | 0.013 | 0.208 | 0.268 | 0.473 | 0.355 |
| P-value  | 0.289 | 0.002 | 0.000 | 0.000 | 0.000 |
| TRIM22  | Partial cor | 0.288 | 0.401 | 0.105 | 0.213 | 0.473 | 0.404 |
| P-value  | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 |

*The bold fonts in Table 1 indicate significant correlations between hub genes and immune infiltrating cells (P < 0.05). The correlation degree is judged by the correlation coefficient cor. Positive cor means a positive correlation and negative cor means a negative correlation. The closer the absolute value of cor is to 1, the stronger the correlation is.

| Table 2 | The results of relevance analysis between 5 gene expressions and immune checkpoint expressions |
|---------|----------------------------------|
| Variable | PDCD1 | CD274 | CTLA4 | HAVCR2 | TOX |
| CXCL13  | Cor | 0.666 | 0.517 | 0.764 | 0.580 | -0.013 |
| P.value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.816 |
| IDO1    | Cor | 0.436 | 0.538 | 0.505 | 0.418 | -0.077 |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.180 |
| PI3     | Cor | 0.229 | 0.105 | 0.214 | 0.238 | -0.176 |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.002 |
| SPP1    | Cor | 0.301 | 0.354 | 0.455 | 0.720 | -0.207 |
| P-value | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.438 |

*The annotation is same as Table 1.

Fig. 4 Correlation analysis among prognosis-related hub genes and immune features. a Visualization of correlation analysis results between five genes and immune infiltrating cells. The vertical axes are CXCL13, IDO1, PI3, SPP1 and TRIM22 from top to bottom; From left to right the horizontal axes are tumor purity, B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils and dendritic cells. b Visualization of correlation analysis results between five genes and immune checkpoint gene expressions. The vertical axes are CXCL13, IDO1, PI3, SPP1 and TRIM22 from top to bottom. The horizontal axes are PDCD1, CD274, CTLA4, HAVCR2 and TOX from left to the right. TIMER website includes 303 samples from TCGA.
Fig. 4 (See legend on previous page.)
and CD4+ T cells, neutrophils, dendritic cells; TRIM22 and CD8+ T cells, CD4+ T cells, macrophages and other immune cells were consistent with TIMER results (Fig. S2c). It is suggested that CXCL13, IDO1, PI3, SPP1 and TRIM22 were closely related to the immune process of HGSOC.

The results indicated that CXCL13, IDO1, PI3, SPP1 and TRIM22 played significant roles in the immune process of HGSOC, which could participate in a variety of immunocytes infiltration and were closely related to the gene expressions of immune checkpoints. Especially the co-expression between CXCL13 and immune checkpoint CTLA4, the co-expression between SPP1 and immune checkpoint HAVCR2, as well as the co-expression between TRIM22 and immune checkpoint CD274 were strong (cor > 0.7) (Table 2; Fig. 4b).

**Histological verification of CXCL13, IDO1, PI3, SPP1, TRIM22**

Compared with the paracancerous tissues, the expression of CXCL13 (P = 0.0093), IDO1 (P = 0.0068), PI3 (P = 0.0161), SPP1 (P = 0.0122) in tumor tissues was significantly increased, while TRIM22 (P = 0.0342) was significantly decreased. These results were consistent with the bioinformatics analysis (Fig. 5).

**GSEA analysis of CXCL13, IDO1, PI3, SPP1, TRIM22**

The results of GSEA analysis revealed that CXCL13 was enriched in the pathways of antigen processing and presentation, natural killer cell mediated cytotoxicity, chemokine signaling, et al. (Fig. 6a). IDO1 was enriched in the pathways of natural killer cell mediated cytotoxicity, antigen processing and presentation, et al. (Fig. 6b). PI3 was enriched in the pathways of antigen processing and presentation, toll like receptor signaling (Fig. 6c). SPP1 was enriched in the pathways of chemokine signaling, natural killer cell mediated cytotoxicity, et al. (Fig. 6d). TRIM22 was enriched in the pathways of chemokine signaling, T cell receptor signaling, natural killer cell mediated cytotoxicity, et al. (Fig. 6e).

**Correlation analysis of CXCL13, IDO1, PI3, SPP1, TRIM22 with clinicopathological features and prognosis**

According to the clinical information of patients in TCGA-OV database, the correlation analysis between the expression of five genes and the clinicopathological features of HGSOC showed that the expression of residual genes had no significant correlation with clinical stage and grade status, except that the patients with high expression of SPP1 were more prone to lymphatic invasion (Additional file 8: Fig.S3a–c).
Consistent with the results of KM analysis in "Identification of prognosis-related DEGs and construction of PPI network and core module" section, COX regression analysis suggested that CXCL13, IDO1, SPP1, TRIM22 were protective factors for the prognosis of HGSOC patients, while PI3 was a risk factor (Additional file 8: Fig. S3d).

Fig. 6 GSEA analysis. Enrichment immune-related pathways of CXCL13 (a), IDO1 (b), PI3 (c), SPP1 (d), TRIM22 (e) (n = 321). The vertical axis represents ES, while the horizontal axis represents the gene set distribution. The GSEA software estimates the statistical significance (nominal P value) of the ES by using an empirical phenotype-base permutation test procedure and adjust the estimated significance level of account for multiple hypothesis [43].
Analysis based on chemotherapy sensitivity of tumor immune-related genes

We divided patients from GSE15622 dataset into paclitaxel resistant group (PR), paclitaxel sensitive group (PS), carboplatin resistant group (CR) and carboplatin sensitive group (CS) according to their information about chemotherapy sensitivity. The results of GO analysis showed that there were some degrees of immune activation both in two chemo sensitive groups. For example, the processes of leukocyte migration, regulation of leukocyte migration were enriched in PS group (Additional file 9: Fig. S4a), while the processes of neutrophil degranulation, neutrophil activation, neutrophil mediated immunity were enriched in CS group (Additional file 9: Fig. S4c).

Furthermore, we compared the expressions of CXCL13, IDO1, PI3, SPP1 and TRIM22 between groups. The results showed that TRIM22 was significantly different between PR and PS group (Fig. 7e), while the expressions of IDO1 and PI3 were significantly different between CR and CS group (Fig. 7b, c). And it indicated that single gene expression of IDO1, PI3 and TRIM22 could influence the chemotherapy sensitivity of ovarian cancer patients. Patients with high expression of TRIM22 might be more sensitive to paclitaxel, while patients with low expression of IDO1 and PI3 might be more sensitive to carboplatin.

Application evaluation of prediction models PTX score and CBP score

We found that single gene expressions of IDO1, PI3 and TRIM22 could influence the chemotherapy sensitivity of OC patients in “Analysis based on chemotherapy sensitivity of tumor immune-related genes” section. At the same time, the previous analysis of the study showed that the coding proteins of CXCL13, IDO1, PI3, SPP1 and TRIM22 had a strong potential relevance. And they

---

Fig. 7 Correlation analysis between tumor immune-related genes and chemotherapy sensitivity. Comparation of single gene expression between paclitaxel resistant group (n = 12) and paclitaxel sensitive group (n = 24) in ovarian cancer patients (left), and the comparation of single gene expression between carboplatin resistant group (n = 11) and carboplatin sensitive group (n = 18) (right). a CXCL13, b IDO1, c PI3, d SPP1, e TRIM22
were all closely related to the immunocyte infiltration and immune checkpoints of HGSOC. Thus, the scoring model based on the gene expressions of CXCL13, IDO1, PI3, SPP1 and TRIM22 from GSE15622 dataset and constructed by lasso algorithm could better predict the sensitivity of ovarian cancer patients to chemotherapeutic drugs than which based on single gene.

The construction of PTX score prediction model according to gene expression profiles of patients with paclitaxel treatment from GSE15622 was as follows:

\[
PTXscore = -0.41 \times IDO1 - 0.57 \times PI3 + 0.18 \times SPP1 + 0.83 \times TRIM22
\]

We calculated PTX scores in every sample and found it had a significant difference between PR group and PS group. The PTX scores were generally higher in PS group (Fig. 8b). Besides, the percentage of patients who were sensitive to paclitaxel treatment in high-PTX score group was greatly increased when patients were divided into high-PTX score group and low-PTX score group according to the median value (Fig. 8c). The AUC of ROC curve showed that the accuracy of judging sensitivity of patients to paclitaxel by PTX score (AUC = 0.747) was higher than those by the expression of single gene including TRIM22 (AUC = 0.715), PI3 (AUC = 0.625), SPP1 (AUC = 0.635), IDO1 (AUC = 0.590) and CXCL13 (AUC = 0.507) (Fig. 8d, e).

Then we calculated PTX scores of 320 HGSOC cases in TCGA-OV database according to the model and found that the overall survival rate of high-PTX score group increased significantly (Fig. 8f).

---

**Fig. 8** PTX score paclitaxel sensitivity prediction model. **a** Gene coefficients of PTX score paclitaxel sensitivity prediction model. **b** Comparison of PTX scores between paclitaxel resistant group (blue) and paclitaxel sensitive group (yellow). **c** Proportions of paclitaxel resistant (orange) and sensitive (green) patients in high PTX score group and low PTX score group. **d** ROC curves of paclitaxel sensitivity in ovarian cancer patients evaluated by TRIM22 (black), PI3 (green), SPP1 (purple), IDO1 (blue) and CXCL13 (yellow). The larger the AUC, the more accurate the judgment. **e** ROC curve of paclitaxel sensitive in ovarian cancer patients evaluated by PTX score (red). **f** Survival curves by KM analysis of PTX score in TCGA database (n = 320). The horizontal axis is the time, and the longitudinal axis is the overall survival rate of corresponding time. The red color represents high PTX score group and blue color represents low PTX score group.
Next, the construction of CBP score prediction model according to gene expression profiles of patients with carboplatin treatment from GSE15622 was as follows:

\[
\text{CBPscore} = 1.01 \times \text{CXCL13} - 1.82 \times \text{IDO1} - 1.10 \times \text{PI3} - 0.14 \times \text{SPP1} - 1.18 \times \text{TRIM22}
\]

We calculated CBP scores in every sample and found it had a significant difference between CR and CS group. The CBP scores were generally higher in CS group (Fig. 9b). Besides, the percentage of patients who were sensitive to carboplatin treatment in high-CBP score group was greatly increased when patients were divided into high-CBP score group and low-CBP score group according to the median value (Fig. 9c). The AUC of ROC curve showed that the accuracy of judging sensitivity of patients to carboplatin by CBP score (AUC = 0.830) was higher than those by the expression of single gene including TRIM22 (AUC = 0.601), PI3 (AUC = 0.722), SPP1 (AUC = 0.707), IDO1 (AUC = 0.692) and CXCL13 (AUC = 0.520) (Fig. 9d, e).

Then we calculated CBP scores of 320 HGSOC cases in TCGA-OV database according to the model and found that the overall survival rate of high-CBP score group increased significantly (Fig. 9f).

Univariate and multivariate COX regression analysis showed that age, residual tumor lesion, CBP score and PTX score were independent prognostic factors for HGSOC patients (Additional file: Fig.S4e). Patients older than 70 years, HGSOC residual lesions larger than 1 cm, low CBP score, and low PTX score were more likely to have poor prognosis (Additional file: Fig.S4f).

[Fig. 9 CBP score carboplatin sensitivity prediction model. a Gene coefficients of CBP score carboplatin sensitivity prediction model. b Comparison of CBP scores between carboplatin resistant group (blue) and carboplatin sensitive group (yellow). c Proportions of carboplatin resistant (orange) and sensitive (green) patients in high CBP score group and low CBP score group. d ROC curves of carboplatin sensitivity in ovarian cancer patients evaluated by TRIM22 (black), PI3 (green), SPP1 (purple), IDO1 (blue) and CXCL13 (yellow). The larger the AUC, the more accurate the judgment. e ROC curve of carboplatin sensitive in ovarian cancer patients evaluated by CBP score (red). f Survival curves by KM analysis of CBP score in TCGA database (n = 320). The horizontal axis is the time, and the longitudinal axis is the overall survival rate of corresponding time. The red color represents high CBP score group and blue color represents low CBP score group.]
The above results confirmed that two models based on the gene expressions of CXCL13, IDO1, PI3, SPP1 and TRIM22 could be applied to predict the sensitivity of HGSOC patients to paclitaxel and carboplatin, and they had great judgment value. Meanwhile, the overall survival rate of patients from high chemotherapy sensitivity group was higher, which indicated that PTX score and CBP score could be well used to predict the chemotherapy sensitivity and prognosis risk of ovarian cancer patients.

Discussion

Ovarian cancer is a common gynecological tumor along with poor prognosis, the outcome of which is associated with immunocyte infiltration. Difficulty in early diagnosis and the recurrence because of resistance to chemotherapy generally makes the high mortality of ovarian cancer patients. HGSOC is usually treated with surgical resection combined with chemotherapy of paclitaxel and carboplatin (bevacizumab is added in some cases) as the most common subtype of epithelial ovarian cancer [12]. HGSOC often happens to elderly women in advanced stage of FIGO, and they intend to develop drug resistance with time passing by, which leads to a bad outcome although chemotherapeutic drugs work well in the initial stage.

The poor prognosis of HGSOC is correlated with immunocyte infiltration and immunotherapy, but the research about comprehensive analysis of these three aspects is rare. Our study screened HGSOC prognosis-related genes and explored whether they were equally important in tumor immune response and treatment. Finally, we got prognostic markers with potential application value and could also be used as immunotherapy molecular targets of HGSOC. At the same time, score models based on these target genes could effectively assess the chemosensitivity and prognosis of patients.

First, we got 491 DEGs of HGSOC from GEO, TCGA and GTEx databases, and after prognosis analysis we found 37 genes could influence overall survival rate of patients. And we screened one core module which included 11 hub genes by PPI to get potential molecular targets of HGSOC. The same time, score models based on these target genes could effectively assess the chemosensitivity and prognosis of patients.

In particular, CXCL13 and immune checkpoint CTLA, SPP1 and immune checkpoint HAVCR2, as well as TRIM22 and immune checkpoint CD274 showed strong collinear expression. It also indicated that these five genes played significant roles in the immune process of HGSOC as potential immunotherapy molecular targets. What's more, the results of RT-qPCR verified the results of DEGs analysis of public databases. At the same time, single-gene GSEA results showed that the five genes were closely related the immune-related pathways of antigen processing and presentation, T cell receptor signaling and so on.

Lo et al. have reported that the densities of CD3+ T cells, CD8+ T cells and PD-1+ T cells increased in HGSOC after chemotherapy of platinum, and the increase of these T cell subtypes was associated with the presence of immunocytes before treatment, which suggested that platinum chemotherapy could induce expected immune reaction if the necessary immunocytes had already been in the tumor [49]. These studies indicated that the chemosensitivity of HGSOC patients was closely related to the cancer immune microenvironment. According to the dataset expression profiles from GSE15622 and information of patients’ sensitivity to chemotherapeutic drugs, our analysis found that patients with high expression of TRIM22 were more sensitive to paclitaxel, while patients with low expression of IDO1 and PI3 were more sensitive to carboplatin.

At present, the roles of CXCL13, IDO1 and SPP1 in immune process of tumor have been studied. As a chemokine, CXCL13 binds to its homologous receptor CXCR5, participates in the migration and recruitment of lymphocytes, which helps to enhance the immune response of tumor host [50, 51]. CXCL13 could enhance the effectiveness of PD-1 blocking therapy in ovarian cancer [52]. IDO1 can induce the production of inhibitors (ICPIs) can prevent immune escape of tumor and reactivate the immune system to produce an antitumor response by destroying important targets in the process of tumor immune tolerance. The past studies suggested that samples of tumor patients who were reactive to PD1 immune checkpoint inhibitors usually had higher densities of CD3+ T cells, CD8+ T cells and PD-1+ T cells in both invasive margin and center of tumor [48]. Some researchers also found that high level infiltration of CD8+ TILs in HGSOC stroma was associated with higher overall survival rate [49]. Thus, we took further immune evaluation about immune checkpoints and immune infiltrating cells according to 11 hub genes. The results showed that CXCL13, IDO1, PI3, SPP1 and TRIM22 could participate in a variety of immunocytes infiltration and were closely related to the gene expressions of immune checkpoints.

Finally, we got prognostic markers with potential application value and could also be used as immunotherapy molecular targets of HGSOC. At the same time, score models based on these target genes could effectively assess the chemosensitivity and prognosis of patients.

Immunocytes play an essential role in tumor tissue, and an increasing number of studies has shown that they also have clinicopathological significances in predicting prognosis and efficacy [46, 47]. Immune checkpoint inhibitors (ICPIs) can prevent immune escape of tumor and reactivate the immune system to produce an antitumor response by destroying important targets in the process of tumor immune tolerance. The past studies suggested that samples of tumor patients who were reactive to PD1 immune checkpoint inhibitors usually had higher densities of CD3+ T cells, CD8+ T cells and PD-1+ T cells in both invasive margin and center of tumor [48]. Some researchers also found that high level infiltration of CD8+ TILs in HGSOC stroma was associated with higher overall survival rate [49]. Thus, we took further immune evaluation about immune checkpoints and immune infiltrating cells according to 11 hub genes. The results showed that CXCL13, IDO1, PI3, SPP1 and TRIM22 could participate in a variety of immunocytes infiltration and were closely related to the gene expressions of immune checkpoints.

In particular, CXCL13 and immune checkpoint CTLA, SPP1 and immune checkpoint HAVCR2, as well as TRIM22 and immune checkpoint CD274 showed strong collinear expression. It also indicated that these five genes played significant roles in the immune process of HGSOC as potential immunotherapy molecular targets. What's more, the results of RT-qPCR verified the results of DEGs analysis of public databases. At the same time, single-gene GSEA results showed that the five genes were closely related the immune-related pathways of antigen processing and presentation, T cell receptor signaling and so on.

Lo et al. have reported that the densities of CD3+ T cells, CD8+ T cells and PD-1+ T cells increased in HGSOC after chemotherapy of platinum, and the increase of these T cell subtypes was associated with the presence of immunocytes before treatment, which suggested that platinum chemotherapy could induce expected immune reaction if the necessary immunocytes had already been in the tumor [49]. These studies indicated that the chemosensitivity of HGSOC patients was closely related to the cancer immune microenvironment. According to the dataset expression profiles from GSE15622 and information of patients’ sensitivity to chemotherapeutic drugs, our analysis found that patients with high expression of TRIM22 were more sensitive to paclitaxel, while patients with low expression of IDO1 and PI3 were more sensitive to carboplatin.

At present, the roles of CXCL13, IDO1 and SPP1 in immune process of tumor have been studied. As a chemokine, CXCL13 binds to its homologous receptor CXCR5, participates in the migration and recruitment of lymphocytes, which helps to enhance the immune response of tumor host [50, 51]. CXCL13 could enhance the effectiveness of PD-1 blocking therapy in ovarian cancer [52]. IDO1 can induce the production of
immunosuppressive molecule Tregs by inhibiting the function of T cells, and then produce a series of immunosuppressive effects [53, 54]. Now a variety of small molecule inhibitors targeting IDO1 have entered the clinical research stage [55]. SPP1, which is highly expressed in non-small cell lung cancer, breast cancer and colorectal cancer, evades tumor immunization by regulating the polarization of macrophages in tumor microenvironment, recruiting and inhibiting the activation of T cells, and is related to the prognosis of patients and resistance of drugs [56–62]. Up-regulation of SPP1 was detected in plasma of patients with OC [63]. And in patients with recurrent ovarian cancer, the expression of SPP1 increased in the early stage, which can detect cancer recurrence earlier than that of CA125 alone [64].

PI3 (code Elafin) has been confirmed that it’s highly expressed in HGSOC and is associated with low overall survival rate [65]. PI3 can reduce the sensitivity of epithelial ovarian cancer (EOC) cells to cisplatin and other drugs, but its correlation with immune function has not been revealed [66]. TRIM22 could be greatly upregulated under the stimulations of IFN, LPS and p53 [67]. Current research shows that TRIM22 is highly expressed in glioma and can promote the proliferation of tumor cells, while it plays an anti-cancer role in endometrial cancer [68, 69]. The function and mechanism of TRIM22 in tumor progression need to be further studied.

Past studies showed that CXCL13, IDO1, PI3, SPP1 and TRIM22 were closely correlated with the prognosis, immunization and chemotherapy sensitivity of tumor. We constructed PTX score model to predict the sensitivity of paclitaxel and CBP score model to predict the sensitivity of carboplatin based on the gene expressions of CXCL13, IDO1, PI3, SPP1 and TRIM22. The results showed that they could better predict the sensitivity of ovarian cancer patients to chemotherapeutic drugs than which based on single gene like IDO1, PI3 and TRIM22. After TCGA database was incorporated, we found that the overall survival rate of patients from high chemotherapy sensitivity group (the score was higher than the median) was higher, and CBP score and PTX score could better predict the sensitivity of chemotherapy for HGSOC. Our exploratory study may provide potential biomarkers and molecular targets for chemotherapy for HGSOC, so as to help improve clinical outcomes of patients.

Conclusions
In conclusion, through comprehensive bioinformatics analysis, 5 candidate genes—CXCL13, IDO1, PI3, SPP1 and TRIM22— were identified, which were closely related to the prognosis, immunocyte infiltration, immune checkpoints, and chemotherapy sensitivity of HGSOC. And based on this, two scoring models—PTX score and CBP score— were constructed to effectively predict chemotherapy sensitivity to paclitaxel and carboplatin and the prognosis for patients with HGSOC. Our exploratory study may provide potential biomarkers and molecular targets for chemotherapy for HGSOC, so as to help improve clinical outcomes of patients.

**Abbreviations**
OC: Ovarian cancer; HGSOC: High grade serous ovarian cancer; GEO: Gene Expression Omnibus; DEGs: Differential expressed genes; DEPGs: Prognosis related DEGs; DEPHGs: Hub genes of DEPGs; IDEPHGs: Immune-related DEPHGs; OS: Overall survival; PPI: Protein–protein interaction; STRING: Search tool for the retrieval of interacting genes; MCODE: Molecular complex detection; ssGSEA: Single sample gene set enrichment analysis; TILs: Tumor-infiltrating lymphocytes; DCs: Dendritic cells; aDCs: Activated dendritic cells; iDCs: Immature dendritic cells; pDCs: Plasmacytoid dendritic cells; APC: Antigen presentation response; ICPIs: Immune checkpoint inhibitors; PTX: Paclitaxel; CBP: Carboplatin; AUC: Area under curve.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12935-021-02295-y.

---

**Additional file 1:** Table S1. 29 immune signatures represented as 29 different gene sets.

**Additional file 2:** Table S2. The results of KM analysis of DEGs of HGSOC based on TCGA database.

**Additional file 3:** Table S3. The results of relevance analysis between DEPHGs of HGSOC and immunocytes (all results).

**Additional file 4:** Table S4. The results of relevance analysis between gene expressions and immune checkpoint expressions (all results).

**Additional file 5:** Table S5. Primer Sequences in RT-qPCR.

**Additional file 6:** Fig. S1. A flow chart showing the whole procedures in this study.

**Additional file 7:** Fig. S2. CYBERSORT analysis showing the immune characteristics in HGSOC. a. The proportion of 22 kinds of immune cells in each sample. b. Comparison of immune infiltrating cells between normal ovarian epithelium samples (green) and HGSOC samples (yellow) in TCGA+GTEx cohort (tumor tissues form TCGA: n=321, normal tissues from GTEx: n=88). The differences were analyzed by Wilcoxon signed rank test. c. Association between 22 kinds of immune cells and 5 genes expression. Red indicates negative correlation whereas blue indicates positive correlation. Correlation coefficient are labeled on the junction points.

**Additional file 8:** Fig. S3. Clinicopathological features and prognosis correlation analysis. a-c. Association between genes expression and clinicopathological features in HGSOC. Significance is determined by Wilcoxon rank sum test (*, P<0.05). a. Clinical stage status (I: 1 case; II: 23 cases; III: 295 cases, IV: 57 cases). b. Clinical grade status (G1: 1 case; G2: 45 cases; G3: 322 cases, G4: 1 case). c. Lymphatic invasion (NO: 48 cases; YES: 101 cases). d. COX regression analysis of CXCL13, IDO1, PI3, SPP1 and TRIM22 (n=320). The points represent the HRs, the horizontal line length represents the 95% CI of each group, and the vertical dashed line represents HR=1.0. HR>1 represents a risk factor whereas HR<1 represents a protective factor.

**Additional file 9:** Fig. S4. GO analysis of GSE15622 and COX regression analysis of TCGA-HGSOC. a. d. GO term enrichment for biological processes (BP), cellular components (CC) and molecular function (MF). a. Paclitaxel sensitive group (n=24). b. Paclitaxel resistant group (n=12). c. Carboplatin sensitive group (n=18). d. Carboplatin resistant group (n=11). e. f. Prognostic value of CBP/PTX score in HGSOC samples from TCGA-OV database (n=287). e. Univariate COX regression analysis showing the
Acknowledgements

Not applicable.

Authors’ contributions

XXM contributed study design and revising the manuscript. LPS contributed analysis instruction and revising the manuscript. HZ contributed performing the data interpretation and drafting manuscript. YW contributed drafting manuscript. HL contributed data interpretation and statistical analysis. All authors read and approved the final manuscript.

Funding

This study was supported by grants from the Liaoning Natural Science Foundation (No. 201202282).

Availability of data and material

The datasets generated and analyzed during the current study are available in the GEO (https://www.ncbi.nlm.nih.gov/geo/), UCSC (http://xenabrowser.net/hub/) repository.

Declarations

Ethics approval and consent to participate

All enrolled patients signed informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

1Department of Gynecology, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China. 2Tumor Etiology and Screening Department of Cancer Institute and General Surgery, Key Laboratory of Cancer Etiology and Prevention in Liaoning Education Department, and Key Laboratory of Gastrointestinal Cancer Etiology and Prevention in Liaoning Province, The First Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China. 3Department of Clinical Laboratory, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People’s Republic of China.

Received: 2 August 2021    Accepted: 21 October 2021

Published online: 04 November 2021

References

1. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.
2. Coleman RL, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18(6):779–91.
3. Volpe J, Filippi JG, Cooper OR, Penson RT. Frontline therapy of ovarian cancer: trials and tribulations. Curr Opin Obstet Gynecol. 2018;30(1):1–6.
4. Al-Alem LF, et al. Ovarian cancer stem cells: what progress have we made? Int J Biochem Cell Biol. 2019;107:92–103.
5. Odusimi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28(suppl_8):vi1–7.
6. Vergote I, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol. 2018;19(12):1680–7.
7. Kuroki L, Guntupalli SR. Treatment of epithelial ovarian cancer. BMJ. 2020;371;m3773.
8. Pujade-Lauraine E, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302–8.
9. Markman M, et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum- and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;101(3):436–40.
10. Perales-Puchalt A, et al. Follicle-stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target. Clin Cancer Res. 2017;23(2):441–53.
11. Lisio MA, Fu L, Goyeneche A, Guo ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20(4):952.
12. Jiménez-Sánchez A, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nat Genet. 2020;52(6):582–93.
13. van Zyl B, Tang D, Bowden NA. Biomarkers of platinum resistance in ovarian cancer: what can we use to improve treatment? Endocr Relat Cancer. 2018;25(5):R303-r318.
14. Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol. 2018;148(1):204–12.
15. Elias KM, Guo J, Bast RC Jr. Early detection of ovarian cancer. Hematol Oncol Clin North Am. 2018;32(6):903–14.
16. Yang WL, Lu Z, Bast RC Jr. The role of biomarkers in the management of epithelial ovarian cancer. Expert Rev Mol Diagn. 2017;17(6):577–91.
17. Muinao T, Deka Boruah HP, Pal M. Diagnostic and Prognostic Biomarkers in ovarian cancer and the potential roles of cancer stem cells—an updated review. Exp Cell Res. 2018;362(1):1–10.
18. Hv wang WT, Adams SF, Tahirovic H, Hageman IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192–8.
19. Saito K, Ohita S, Kawakami Y, Yoshida K, Toda M. Functional analysis of KIF2A0, a potential immunotherapeutic target for glioma. J Neurooncol. 2017;132(1):63–74.
20. Strickland KC, et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serum ovarian cancer. Oncotarget. 2016;7(12):13587–98.
21. Intlekofer AM, Thompson CB. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 2013;94(1):25–39.
22. Fan CA, Reader J, Roque DM. Review of immune therapies targeting ovarian cancer. Curr Treat Options Oncol. 2018;19(12):74.
23. Han manishi J, Mandai M, Konishi I. Immune checkpoint inhibition in ovarian cancer. Int Immunol. 2016;28(7):339–48.
24. Leek JT, Johnson WE, Parker HS, Jaffe AE, Storey JD. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics. 2012;28(6):882–3.
25. Yeung TL, et al. TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment. Cancer Res. 2013;73(16):5016–28.
26. Donn ininger H, et al. Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways. Oncogene. 2004;23(49):8065–77.
27. Bonome T, et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 2008;68(3):1547B–86.
28. Ahmed AA, et al. The extracellular matrix protein TGFβ1 induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel. Cancer Cell. 2007;12(6):514–27.
29. Deng M, Brägelmann J, Schulze JL, Perner S. TGF-β1: a potential target in ovarian cancer. Cancer. 2011;117(2):213–21.
30. Navarro Gonzalez J, et al. The UCSC genome browser database: 2021 update. Nucleic Acids Res. 2021;49(D1):D1046–d1057.
31. Consortium G. The genotype-tissue expression (GTEx) project. Nat Genet. 2013;45(6):580–5.
32. Ritchie ME, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
33. Ito K, Murphy D. Application of ggplot2 to pharmacometric graphics. CPT Pharmacometrics Syst Pharmacol. 2013;2(10):e79.
34. Szklarczyk D, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447–452.
35. Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2.
36. Charoentong P, et al. Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade. Cell Rep. 2017;18(1):248–62.
37. He Y, Jiang Z, Chen C, Wang X. Classification of triple-negative breast cancers based on Immunogenomic profiling. J Exp Clin Cancer Res. 2018;37(1):237.
38. Blindea G, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39(4):782–95.
39. Hänelmann S, Castelo R, Guinney J. GSVa: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 2013;14:7.
40. Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612.
41. Newman AM, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–7.
42. Li T, et al. TIMER: a web server for comprehensive analysis of tumor-immune cell populations in cancer bulk genomic data. Nucleic Acids Res. 2018;46(D1):D383–D391.
43. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
44. Garnelo M, et al. Interaction between tumour-infiltrating B cells and CD8+ T cell activation and tumor immune evasion. J Clin Invest. 2017;128(12):5549–60.
45. Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenet. 2020;5(2):31.
46. Li T, et al. TIMIER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):108–10.
47. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–50.
48. Yu G, Wang LG, Han Y, He QY. ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16(5):284–7.
49. Engebretsen S, Bohlin J. Statistical predictions with glmnet. Clin Epigenet. 2019;11(1):123.
50. Garnelo M, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66(2):342–51.
51. Kurebayashi Y, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–41.
52. Lo CS, et al. Neoadjuvant chemotherapy of ovarian cancer results in three patterns of tumour-infiltrating lymphocyte response with distinct implications for immunotherapy. Clin Cancer Res. 2017;23(4):925–34.
53. Liu Y, et al. Tumor-repopulating cells induce PD-1 expression in CD8(+) T cells by transferring kynurenine and AhR activation. Cancer Cell. 2018;33(3):480–494.e487.
54. Mezrich JD, et al. An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol. 2010;185(6):3190–8.
55. Lin Y, Zhang H, Niu T, Tang ML, Chang J. Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) and histone deacetylase 1 (HDAC1) dual inhibitors derived from the natural product saprothoquinone. Molecules. 2020;25(19):4494.
56. Klement JD, et al. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion. J Clin Invest. 2018;128(12):5549–60.
57. Wei J, et al. Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019;129(1):137–49.
58. Ouyang X, et al. Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer. Onco Targets Ther. 2018;11:5933–41.
59. He Y, et al. Osteopontin/CD44 immune checkpoint controls matrix components that promote chemoresistant metastasis. EMBO Mol Med. 2018;10(10):e9003.
60. Wei R, et al. In vitro and clinical data analysis of Osteopontin as a prognostic indicator in colorectal cancer. J Cell Mol Med. 2018;22(9):4097–105.
61. Ng L, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015;2015:247892.
62. Schorge JO, et al. Osteopontin as an adjunct to CA125 in detecting recurrent ovarian cancer. JAMA. 2002;287(13):1671–9.
63. Schorge JO, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002;287(13):1671–9.
64. Labedi-Galy SI, et al. Elafin drives poor outcome in high-grade serous ovarian cancers and basal-like breast tumors. Oncogene. 2015;34(3):373–83.
65. Wei H, Hellstrom KE, Hellstrom I. Elafin selectively regulates the sensitivity of ovarian cancer cells to genotoxic drug-induced apoptosis. Gynecol Oncol. 2012;125(3):727–33.
66. McNab FW, Rajbaumer R, Stoye JP, O’Garra A. Tripartite-motif proteins and innate immune regulation. Curr Opin Immunol. 2011;23(1):46–56.
67. Lin Y, et al. Osteopontin overexpression induced tumor progression and chemoresistance to oxaliplatin through induction of stem-like properties in human colorectal cancer. Stem Cells Int. 2015;2015:247892.